A Phase 1/2 Study of GRT-C903/GRT-R904, a Vaccine Targeting Shared Neoantigens, in Combination with Immune Checkpoint Blockade for Patients with Advanced Solid Tumors
Study of A Vaccine Targeting Shared Neoantigens in Subjects with Advanced Solid Tumors
Sponsor: Gritstone Oncology
Enrolling: Male and Female Patients
IRB Number: AAAS5371
U.S. Govt. ID: NCT03953235
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to learn more about the safety of a cancer vaccine that teaches the immune system to recognize and possibly destroy tumor cells, and to assess how well the vaccine works. The vaccine has two components. One of them is study drug GRT-C903, and the other is GRT-C904. The vaccine works by stimulating the immune system, which then fights tumors by recognizing and destroying tumor cells. This vaccine will be used in combination with FDA-approved drugs ipilimumab and nivolumab, which are medications that activate the immune system. The overall study treatment, which consists of the vaccine plus the ipilimumab and nivolumab, is not yet approved by the FDA, and is being tested in this study to see if it is safe and if it can help your body control your cancer.
Brian Henick, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have colorectal cancer or non-small-cell lung cancer (NSCLC)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator